68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma
Comparison of 68Ga-pentixather and 68Ga-pentixafor PET/CT in Patients With Multiple Myeloma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Li Huo, MD.
- Phone Number: 86-10-69155537
- Email: huoli@pumch.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100005
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Li Huo, MD.
- Phone Number: 86-10-69155537
- Email: huoli@pumch.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Suspected or confirmed untreated multiple myeloma (MM), relapsed MM, MM in remission
- Signed written consent
Exclusion Criteria:
- pregnancy
- breastfeeding
- known allergy against pentixather or pentixafor
- any medical condition that in the opinion of the investigator, may significantly interfere with study compliance.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT scan
Participants with multiple myeloma will perform 68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT within 7-day interval
|
After intravenous injection of 68Ga-pentixather, PET/CT scan will be performed.
Other Names:
After intravenous injection of 68Ga-pentixafor, PET/CT scan will be performed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Metabolic parameter
Time Frame: through study completion, an average of 2 years
|
Comparison of metabolic parameter (SUVmax) between 68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT.
|
through study completion, an average of 2 years
|
|
PET-positive diffuse bone marrow involvement
Time Frame: through study completion, an average of 2 years
|
Comparison of the number of diffuse bone marrow involvement between 68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT.
|
through study completion, an average of 2 years
|
|
PET-positive focal bone marrow lesions
Time Frame: through study completion, an average of 2 years
|
Comparison of the number of focal bone marrow lesions between 68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT.
|
through study completion, an average of 2 years
|
|
PET-positive extramedullary lesions
Time Frame: through study completion, an average of 2 years
|
Comparison of the number of extramedullary lesions between 68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT.
|
through study completion, an average of 2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse effects
Time Frame: through study completion, an average of 2 years
|
Types of adverse events.
|
through study completion, an average of 2 years
|
|
Tumor burden assessment
Time Frame: through study completion, an average of 2 years
|
The correlation between metabolic parameter (SUVmax) in 68Ga-pentixather PET/CT and clinical staging
|
through study completion, an average of 2 years
|
|
Follow-up assessment
Time Frame: through study completion, an average of 2 years
|
The correlation between metabolic parameter (SUVmax) in 68Ga-pentixather PET/CT and follow-up parameter (PFS).
|
through study completion, an average of 2 years
|
|
CXCR4 expression in biopsies and metabolic parameters in PET
Time Frame: through study completion, an average of 2 years
|
The correlation between CXCR4 expression in biopsies and metabolic parameter (SUVmax) in PET.
|
through study completion, an average of 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Qiao Yang, MD., Peking Union Medical College Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
Other Study ID Numbers
- PUMCH-MM-pentixather
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.